BOD approve the 2022 second quarter consolidated financial statements
· Issued by AmCad BioMed Corporation
Close
Today's Information
Provided by: AmCad BioMed Corporation
SEQ_NO
1
Date of announcement
2022/08/09
Time of announcement
15:29:06
Subject
AmCad BOD approve the 2022 second quarter consolidated
financial statements
Date of events
2022/08/09
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/09
2.Date of the audit committee approved:2022/08/09
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):34,579
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):21,715
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(24,029)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(19,880)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(19,880)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(19,214)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(0.36)
11.Total assets end of the period (thousand NTD):588,958
12.Total liabilities end of the period
(thousand NTD):25,014
13.Equity attributable to owners of parent end of the
period (thousand NTD):468,555
14.Any other matters that need to be specified:None
